MEDIAN Technologies, Microsoft Collaborate
News Jul 01, 2016
MEDIAN Technologies and Microsoft have announced a joint global initiative in the rapidly growing Precision Medicine market to develop new cancer detection, diagnosis and monitoring methods using Big Data analytics. As part of the initiative, MEDIAN Technologies will collaborate with Microsoft to install its groundbreaking imaging biomarker phenotyping system (IBIOPSY™) on the Microsoft Azure cloud computing platform.
On Azure, IBIOPSY™ will provide capabilities for processing and analyzing medical images, extracting biomarkers of disease in real time for cancer diagnosis and treatment purposes. “Precision Medicine is about to revolutionize how diagnostic and biological data is used to pinpoint and deliver care that is preventive, targeted and effective” said Fredrik Brag Chief Executive Officer at MEDIAN Technologies.
“Extracting biomarkers of disease from medical images is at the core of the Precision Medicine effort. Big Data computing and analytics will allow efficient processing and analysis of imaging biomarkers which is essential for early detection of cancer and monitoring of new targeted cancer treatments. Our collaboration with Microsoft will allow us to deliver these solutions into routine clinical practice on a global scale on the Azure Cloud Computing platform.”
“Microsoft Innovation teams are committed to providing their technical expertise to health professionals who use medical images in their daily routine. We are proud to collaborate with MEDIAN on the IBIOPSY™ project and to bring innovative technologies at the service of cancer research”, said Bernard Our ghanlian, Chief Technology & Security Officer at Microsoft France.
“Indeed, we are, more than ever committed to addressing the biggest challenges in cancer detection, diagnosis and monitoring, by offering access to the latest and most innovative technologies. By taking advantage of the powerful Microsoft Azure cloud platform, IBIOPSY™ will provide faster imaging and health data analysis and will accelerate the discovery and delivery of new biomarkers for cancer diagnosis and treatment monitoring.”
IBIOPSY™ will eventually be made available to medical facilities and physicians in the US, Europe, and Asia to meet the image processing and data analytics needs created by the next generation of personalized cancer therapies and the explosive growth in medical imaging data. MEDIAN Technologies and Microsoft will work together to help medical centers take advantage of the Azure capabilities.
Also MEDIAN Technologies and Microsoft collaboration will focus on the development of novel predictive analytics methods based on machine learning and encryption capabilities that will be available on Azure.
New Microscope Captures Detailed 3-D Movies of Cells Deep Within Living SystemsNews
Merging lattice light sheet microscopy with adaptive optics reveals the most detailed picture yet of subcellular dynamics in multicellular organisms.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE